Time (weeks) | Â | 0 | 4 | 8 | ptrial ptime ptrial * ptime |
---|---|---|---|---|---|
BMI (kg/m2) | Placebo (N = 28) | 26.6 ± 2.9 | 26.7 ± 3.0 | 26.7 ± 3.0 | 0.7 0.7 0.2 |
Supplement (N = 30) | 27.0 ± 2.0 | 26.8 ± 2.0 | 26.8 ± 1.9 | ||
Systolic blood pressure (mm Hg) | Placebo (N = 28) | 78.5 ± 8.8 | 74.0 ± 8.8 | 72.4 ± 8.2 | 0.8 0.1 0.1 |
Supplement (N = 30) | 74.5 ± 8.5 | 75.3 ± 8.6 | 73.3 ± 8.4 | ||
Diastolic blood pressure (mm Hg) | Placebo (N = 28) | 126.9 ± 10.2 | 120.2 ± 12.7 | 119.2 ± 9.7 | 0.8 0.1 0.2 |
Supplement (N = 30) | 122.7 ± 10.5 | 117.4 ± 10.4 | 120.0 ± 7.4 | ||
Glucose (mmol/L) | Placebo (N = 28) | 5.31 ± 0.56 | 5,27 ± 0.54 | 5.32 ± 0.63 | 0.09 0.3 0.1 |
Supplement (N = 30) | 5.62 ± 0.71 | 5.63 ± 0.73 | 5.46 ± 0.69 | ||
Cholesterol (mmol/L) | Placebo (N = 28) | 4.85 ± 1.11 | 4.71 ± 0.98 | 4.69 ± 1.07 | 0.1 0.06 0.9 |
Supplement (N = 30) | 5.20 ± 1.09 | 5.10 ± 1.04 | 5.07 ± 1.11 | ||
HDL-chol (mmol/L) | Placebo (N = 28) | 1.27 ± 0.37 | 1.23 ± 0.35 | 1.25 ± 0.35 | 0.4 0.3 0.6 |
Supplement (N = 30) | 1.19 ± 0,41 | 1.17 ± 0.37 | 1.16 ± 0.37 | ||
LDL-chol (mmol/L) | Placebo (N = 28) | 3.20 ± 1.13 | 3.12 ± 1.06 | 3.06 ± 1.17 | 0.1 0.2 0.9 |
Supplement (N = 30) | 3.58 ± 1.18 | 3.53 ± 1.16 | 3.49 ± 1.18 | ||
Triacylglycerols (mmol/L) | Placebo (N = 28) | 0.82 ± 0.44 | 0.83 ± 0.54 | 0.81 ± 0.46 | 0.1 0.6 0.1 |
Supplement (N = 30) | 1.04 ± 0.73 | 0.97 ± 0.68 | 1.06 ± 0.78 | ||
Uric acid (mmol/L) | Placebo (N = 28) | 0.28 ± 0.07 | 0.27 ± 0.07 | 0.28 ± 0.07 | 0.5 0.3 0.2 |
Supplement (N = 30) | 0.27 ± 0.07 | 0.27 ± 0.06 | 0.27 ± 0.07 |